Wyeth has announced a national trial of its experimental drug Desvenlafaxine Sustained Release (DVS SR) for treatment of fibromyalgia pain. (“A study evaluating desvenlafaxine sustained release in adult female outpatients with Fibromyalgia” – Clinicaltrials.gov ID NCT00696787)
The trial, which is looking to recruit some 420 adult females diagnosed with fibromyalgia, will be conducted via 26 centers in 14 states across the U.S.
The 8-week randomized, double blind effectiveness study will include three arms. One group will receive DVS SR, a second group will receive Pfizer’s drug LyricaR (pregabalin), which has received FDA approval as a Fibromyalgia drug, and a third group will receive a placebo (fake) dose.
Desvenlafaxine is a serotonin-norepinephrine reuptake inhibitor drug that won FDA approval earlier in 2008 for treatment of depression. As an SNRI it works to increase the concentration of serotonin and norepinephrine, two neurotransmitters that activate pain-blocking nerves. Lyrica, also used to treat seizures and nerve pain, is thought to “reduce the number of electrical signals that the brain cells send to each other,” though exactly how it works is unknown.
To read more about criteria for inclusion in the study, to review the locations of study centers, and to link to the Trial Manager at Wyeth for further information, see the study’s ClinicalTrials.gov listing.